These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 28689433)

  • 1. Experimental and early investigational drugs for androgenetic alopecia.
    Guo H; Gao WV; Endo H; McElwee KJ
    Expert Opin Investig Drugs; 2017 Aug; 26(8):917-932. PubMed ID: 28689433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New investigational drugs for androgenetic alopecia.
    Valente Duarte de Sousa IC; Tosti A
    Expert Opin Investig Drugs; 2013 May; 22(5):573-89. PubMed ID: 23550739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs under investigation for the treatment of alopecias.
    Ocampo-Garza J; Griggs J; Tosti A
    Expert Opin Investig Drugs; 2019 Mar; 28(3):275-284. PubMed ID: 30642204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options.
    Vasserot AP; Geyfman M; Poloso NJ
    Expert Opin Ther Targets; 2019 Sep; 23(9):755-771. PubMed ID: 31456448
    [No Abstract]   [Full Text] [Related]  

  • 5. Androgen metabolism as it affects hair growth in androgenetic alopecia.
    Kaufman KD
    Dermatol Clin; 1996 Oct; 14(4):697-711. PubMed ID: 9238328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bald statement - Current approaches to manipulate miniaturisation focus only on promoting hair growth.
    Pantelireis N; Higgins CA
    Exp Dermatol; 2018 Sep; 27(9):959-965. PubMed ID: 29787625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational medications in the treatment of alopecia.
    Poulos GA; Mirmirani P
    Expert Opin Investig Drugs; 2005 Feb; 14(2):177-84. PubMed ID: 15757393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.
    Gassmueller J; Hoffmann R; Webster A
    Br J Dermatol; 2008 Jan; 158(1):109-15. PubMed ID: 17986309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatments in alopecia.
    Falto-Aizpurua L; Choudhary S; Tosti A
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):545-56. PubMed ID: 25330928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety concerns when using novel medications to treat alopecia.
    Almohanna HM; Perper M; Tosti A
    Expert Opin Drug Saf; 2018 Nov; 17(11):1115-1128. PubMed ID: 30318935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insight Into the Pathophysiology of Hair Loss Trigger a Paradigm Shift in the Treatment Approach.
    Sadick NS; Callender VD; Kircik LH; Kogan S
    J Drugs Dermatol; 2017 Nov; 16(11):s135-s140. PubMed ID: 29141068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles.
    Randall VA; Jenner TJ; Hibberts NA; De Oliveira IO; Vafaee T
    J Endocrinol; 2008 Apr; 197(1):11-23. PubMed ID: 18372228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia.
    Gupta AK; Carviel J
    Dermatol Surg; 2016 Dec; 42(12):1335-1339. PubMed ID: 27631460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The topical penta-peptide Gly-Pro-Ile-Gly-Ser increases the proportion of thick hair in Japanese men with androgenetic alopecia.
    Iwabuchi T; Takeda S; Yamanishi H; Ideta R; Ehama R; Tsuruda A; Shibata H; Ito T; Komatsu N; Terai K; Oka S
    J Cosmet Dermatol; 2016 Jun; 15(2):176-84. PubMed ID: 27030543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility and validity of minoxidil response testing in androgenetic alopecia.
    Goren A; Shapiro J; Roberts J; McCoy J; Desai N; Zarrab Z; Pietrzak A; Lotti T
    Dermatol Ther; 2015; 28(1):13-6. PubMed ID: 25112173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgenetic alopecia: an evidence-based treatment update.
    Varothai S; Bergfeld WF
    Am J Clin Dermatol; 2014 Jul; 15(3):217-30. PubMed ID: 24848508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness.
    Hamada K; Randall VA
    Br J Dermatol; 2006 Apr; 154(4):609-18. PubMed ID: 16536801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial reversal of androgenetic alopecia with methotrexate therapy for psoriasis.
    Famenini S; Wu JJ
    Cutis; 2013 Sep; 92(3):127-8. PubMed ID: 24153140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating hair growth promoting effects of candidate substance: A review of research methods.
    Ohn J; Kim KH; Kwon O
    J Dermatol Sci; 2019 Mar; 93(3):144-149. PubMed ID: 30904351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia.
    Blume-Peytavi U; Lönnfors S; Hillmann K; Garcia Bartels N
    J Am Acad Dermatol; 2012 May; 66(5):794-800. PubMed ID: 21875758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.